An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays.
The identification of human tumor antigens has potential utility in the diagnosis and treatment of cancers. We demonstrate here a complete strategy to profile immunoreactivity and identify tumor antigens from proteins derived from tumor cell lines. Microarrays of proteins produced from 2-D LC fractionation of prostate tumor cell-line lysates were used to profile immunoreactivity in the sera of prostate cancer patients and control subjects. Cancer-associated immunoreactivity to distinct groups of chromatography fractions was present in about 50% of the patients, with greater immunoreactivity present in patients with non-organ-confined cancer than in patients with organ-confined cancer. We grouped the immunoreactive fractions by similarities in elution order and patterns of immunoreactivity to guide and interpret the MS analysis of selected fractions, which was used to identify the proteins that may be responsible for the immunoreactivity. As a complementary method to further characterize and validate the immunoreactivity of the proteins identified by mass spectrometry, we demonstrate the use of focused microarrays of recombinant proteins. Disease-associated immunoreactivity was confirmed for one of the identified proteins, human Kallikrein 11. These results demonstrate a practical approach to screening, identifying, and validating immunoreactive proteins that could be applied to diverse studies on humoral immune responses.
Van Andel Research Institute, Grand Rapids, MI, USA.
Sara
S
Forrester
Ji
J
Qiu
Leslie
L
Mangold
Alan
A
Partin
David
D
Misek
Brett
B
Phinney
Douglas
D
Whitten
Philip
P
Andrews
Eleftherios
E
Diamandis
Gilbert S
GS
Omenn
Samir
S
Hanash
Brian B
BB
Haab